Market Trends of Kaposi Sarcoma Industry
This section covers the major market trends shaping the Kaposi Sarcoma Market according to our research experts:
Chemotherapy Segment Holds a Significant Market Share
Chemotherapy (chemo) is a treatment of cancer-killing drugs used to kill Kaposi Sarcoma cells. The liposomal anthracyclines and taxol class of systemic chemotherapy medications are the most frequently used to treat Kaposi sarcoma (KS). The segment is driven by the rising Kaposi Sarcoma's prevalence and product launches by the key market players.
According to the study published in Oncologist in August 2022, total dosages of paclitaxel and carboplatin (PCb) chemotherapy are acceptable when administered concurrently with antiretroviral therapy (ART) in patients with human immunodeficiency virus (HIV) with cancer, including those receiving CYP3A4 inhibitors. Thus, increased adoption of chemotherapy is expected to boost segment growth over the forecast period.
Moreover, according to the study published in Clinical Cancer Research in March 2022, the study concluded that Pomalidomide is a safe and effective chemotherapy-sparing medication for the treatment of Kaposi sarcoma in people with or without HIV. Thus, the effectiveness and safety of chemotherapy agents like Paralidomide are expected to increase the adoption of such chemotherapy agents in the treatment of Kaposi sarcoma, thereby boosting segment growth over the forecast period.
Thus, all the above factors are expected to boost segment growth over the forecast period.
North America Holds Largest Market Share in the Global Kaposi Sarcoma Market
North America holds a significant market share in the Kaposi treatment market globally. Important factors contributing to the growth of the market are the increasing number of product approvals, the presence of many market players, a high number of R&D initiatives undergoing treatment, and the diagnosis of Kaposi Sarcoma. Additionally, the increasing prevalence of Kaposi Sarcoma and HIV is bolstering market growth in the region. According to Statistics published by CDC in September 2022, in the US and dependent regions in 2020, 30,635 individuals obtained an HIV diagnosis. This suggests that HIV incidences are high in the country, increasing the demand for diagnostics products, which will drive the studied market.
Furthermore, a growing number of clinical studies in the country will likely support the market's growth. For instance, per the ClinicaTrials.gov updates in July 2022, the study Pomalidomide for Kaposi Sarcoma in People with or Without HIV is under phase II development and expected to launch in the near future. Thus, all the above factors are expected to boost market growth over the forecast period.
